A Phase 2 interventional study of Finerenone (Kerendia, BAY94-8862) and Placebo in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Completed at 115 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.
Sponsored by Bayer · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 2, and was the 3rd registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:
Peter Rossing · Sites in Denmark, Germany, Spain and 1 more country
Ages 18–75
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
The George Institute · Sites in Australia, India, New Zealand and 2 more countries
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 951 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 25 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
49 studies in Renal Insufficiency, Chronic by Bayer: 4 open now, 8 under way, 2 of them phase 3. Of 39 finished, 4 (10%) have results posted.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 4th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 2, and was the 21st registered.
Bayer’s Renal Insufficiency, Chronic studies by the year they started, since 2009.
6 of the studies testing finerenone in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
| NCT07849348Peking University People's HospitalStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | 2027-02 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, from their registry updates:
Among Bayer’s 49 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly. When CKD happens in people with type 2 diabetes mellitus, a condition characterized by high blood sugar levels, CKD is also referred to as diabetic kidney disease (DKD).
FIGARO-BM is an add-on study in which blood draws that were collected in the FIGARO-DKD study are further analyzed. No additional blood draws (also referred to as biological samples) or data will be obtained from the participants, nor will any additional or new study intervention be introduced. No visit or patient contact other than for obtaining the agreement by the patients (also called informed consent) will be required.
Inflammation and scarring are both seen as responsible for worsening of chronic kidney disease. There is much information from animal studies that the study treatment finerenone (BAY94-8862) works against inflammation and against scarring (also called fibrosis) in organs such as the kidney.
In this exploratory study researchers want to learn more about the study treatment finerenone (BAY94-8862). To find this out, this study will examine substances called biomarkers in blood draws from participants in the FIGARO-DKD study. Biomarkers are used as indicators of biological processes, disease processes or responses to medication. The biomarkers that will be examined stand for inflammation, organ scarring (also called fibrosis), blood vessel function and congestion.
The main question of this study is whether there are differences between these biomarkers in the group of participants who received finerenone and the group of participants who received a placebo in the FIGARO-DKD study. A placebo looks like a treatment but does not have any medicine in it. To answer this question, the researchers will compare the levels of these biomarkers between the two groups at different time points after starting the study treatment. Blood samples for this study will be obtained from FIGARO-DKD study sites with a high number of participants who had been treated with finerenone or placebo for at least 24 months. This information will be combined with other information from biomarker examinations already available in the FIGARO-DKD study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
Drug: Finerenone (Kerendia, BAY94-8862)
Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
Drug: Placebo
Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers
The normalized protein expression (NPX) of biomarker levels were analyzed for the set of 27 pre-defined plasma biomarkers. NPX is a unit on log2-scale that is logarithmically related to protein concentration. Linear NPX (2\^NPX) was calcuated for descriptive analyses of the biomarker levels at each visit. Ratios of Visit 11 (36 months of treatment) to Visit 3 (4 months of treatment) were calculated to show the change in the plasma biomarker levels. Visit 3 (4 months of treatment) data were considered as baseline for the biomarker measurements as no pre-dose samples were available from FIGARO-DKD. Note, NPX units (Olink concentration units) are always relative units and can only be interpreted in the context of an individual study, i.e. to compare two conditions or timepoints ("change in NPX"). Equal nominal concentration values (same NPX units) for two different biomarkers measured by Olink Explore does not mean that both markers have the same absolute concentration.
Time frame: At 4 months (Visit 3) of treatment and 36 months (Visit 11) of treatment
The study was conducted at multiple centers in 21 countries/regions between 18 August 2021 (first subject first visit) and 31 December 2021 (last subject last visit).
| Milestone | Finerenone | Placebo |
|---|---|---|
| Started | 483 | 468 |
| Mbfas | 478 | 443 |
| Completed | 478 | 443 |
| Not completed | 5 | 25 |
| Withdrew: Exclusion from mbfas | 5 | 25 |
The normalized protein expression (NPX) of biomarker levels were analyzed for the set of 27 pre-defined plasma biomarkers. NPX is a unit on log2-scale that is logarithmically related to protein concentration. Linear NPX (2\^NPX) was calcuated for descriptive analyses of the biomarker levels at each visit. Ratios of Visit 11 (36 months of treatment) to Visit 3 (4 months of treatment) were calculated to show the change in the plasma biomarker levels. Visit 3 (4 months of treatment) data were considered as baseline for the biomarker measurements as no pre-dose samples were available from FIGARO-DKD. Note, NPX units (Olink concentration units) are always relative units and can only be interpreted in the context of an individual study, i.e. to compare two conditions or timepoints ("change in NPX"). Equal nominal concentration values (same NPX units) for two different biomarkers measured by Olink Explore does not mean that both markers have the same absolute concentration.
| Ratio | Finerenone | Placebo |
|---|---|---|
| Matrilysin (P09237) | 1.014 ± 1.125 | 1.062 ± 1.201 |
| von Willebrand factor (P04275) | 0.979 ± 1.773 | 1.131 ± 1.765 |
| CCN family member 4 (O95388) | 1.109 ± 1.266 | 1.164 ± 1.329 |
| Transforming growth factor beta-1 proprotein (P01137) | 1.122 ± 1.312 | 1.184 ± 1.369 |
| Transforming growth factor beta receptor type 3 (Q03167) | 1.133 ± 1.687 | 1.224 ± 1.649 |
| Interleukin-15 receptor subunit alpha (Q13261) | 1.121 ± 1.402 | 1.179 ± 1.442 |
| Metalloproteinase inhibitor 1 (P01033) | 1.056 ± 1.456 | 1.105 ± 1.381 |
| Pappalysin-1 (Q13219) | 1.088 ± 3.371 | 1.273 ± 3.034 |
| Proto-oncogene tyrosine-protein kinase Src (P12931) | 0.926 ± 2.902 | 1.000 ± 2.492 |
| Protein AMBP (P02760) | 1.034 ± 1.168 | 1.045 ± 1.166 |
| Uromodulin (P07911) | 0.980 ± 1.513 | 0.956 ± 1.388 |
| Aminopeptidase N (P15144) | 1.005 ± 1.263 | 1.020 ± 1.316 |
| Tumor necrosis factor receptor superfamily member 1A (P19438) | 1.151 ± 1.506 | 1.184 ± 1.516 |
| Plasminogen activator inhibitor 1 (P05121) | 0.945 ± 2.089 | 0.972 ± 1.909 |
| CCN family member 2 (P29279) | 1.083 ± 1.548 | 1.103 ± 1.395 |
| Urokinase plasminogen activator surface receptor (Q03405) | 1.109 ± 1.661 | 1.127 ± 1.379 |
| C-C motif chemokine 14 (Q16627) | 1.072 ± 1.617 | 1.092 ± 1.401 |
| C-C motif chemokine 16 (O15467) | 1.044 ± 1.607 | 1.055 ± 1.416 |
| Collagen alpha-1(I) chain (P02452) | 1.101 ± 1.680 | 1.112 ± 1.534 |
| Decorin (P07585) | 1.086 ± 1.202 | 1.088 ± 1.250 |
| C-C motif chemokine 2 (P13500) | 1.001 ± 1.329 | 1.003 ± 1.409 |
| Matrix metalloproteinase-9 (P14780) | 1.074 ± 2.303 | 1.080 ± 2.108 |
| E-selectin (P16581) | 1.009 ± 1.681 | 1.010 ± 1.432 |
| Thrombospondin-2 (P35442) | 1.054 ± 1.533 | 1.056 ± 1.533 |
| Retinoic acid receptor responder protein 2 (Q99969) | 1.035 ± 1.569 | 1.022 ± 1.517 |
| C-X-C motif chemokine 16 (Q9H2A7) | 1.058 ± 1.562 | 1.063 ± 1.330 |
| Dickkopf-related protein 3 (Q9UBP4) | 1.050 ± 1.452 | 1.055 ± 1.427 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Finerenone | — | — | — |
| Placebo | — | — | — |
Modified biomarker full analysis set (mBFAS): All participants with valid informed consent for this biomarker study, which met the following criteria: a. Study enrollment criteria as defined in the study protocol. b. Analyzed biomarker samples at Visit 3 (4 months) and Visit 11 (36 months); Biomarker samples that were shipped at ambient temperatures were not analyzed. c. On Treatment at Visit 3 and Visit 11.
| Age, Continuous(years) | Finerenone | Placebo | Total |
|---|---|---|---|
| Mean | 63.55 ± 9.50 | 64.15 ± 9.65 | 63.84 ± 9.57 |
| Sex: Female, Male(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| Female | 120 | 112 | 232 |
| Male | 358 | 331 | 689 |
| Race (NIH/OMB)(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 173 | 151 | 324 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 8 | 7 | 15 |
| White | 293 | 283 | 576 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Plasma biomarker levels after 4 months of treatment(Linear NPX (2^NPX)) | Finerenone | Placebo | Total |
|---|---|---|---|
| Matrilysin (P09237) | 19.618 ± 1.148 | 18.956 ± 1.203 | NA ± NA |
| von Willebrand factor (P04275) | 3.200 ± 1.793 | 2.338 ± 1.629 | NA ± NA |
| CCN family member 4 (O95388) | 1.600 ± 1.337 | 1.578 ± 1.374 | NA ± NA |
| Transforming growth factor beta-1 proprotein (P01137) | 1.480 ± 1.327 | 1.425 ± 1.349 | NA ± NA |
| Transforming growth factor beta receptor type 3 (Q03167) | 1.583 ± 1.631 | 1.776 ± 1.624 | NA ± NA |
| Interleukin-15 receptor subunit alpha (Q13261) | 1.678 ± 1.432 | 1.614 ± 1.450 | NA ± NA |
| Metalloproteinase inhibitor 1 (P01033) | 1.818 ± 1.450 | 1.824 ± 1.349 | NA ± NA |
| Pappalysin-1 (Q13219) | 0.171 ± 3.066 | 0.164 ± 2.762 | NA ± NA |
| Proto-oncogene tyrosine-protein kinase Src (P12931) | 1.770 ± 2.614 | 1.535 ± 2.229 | NA ± NA |
| Protein AMBP (P02760) | 1.595 ± 1.226 | 1.611 ± 1.225 | NA ± NA |
| Uromodulin (P07911) | 0.582 ± 1.752 | 0.699 ± 1.531 | NA ± NA |
| Aminopeptidase N (P15144) | 1.224 ± 1.273 | 1.248 ± 1.300 | NA ± NA |
| Tumor necrosis factor receptor superfamily member 1A (P19438) | 2.105 ± 1.606 | 2.107 ± 1.575 | NA ± NA |
| Plasminogen activator inhibitor 1 (P05121) | 1.349 ± 2.148 | 1.261 ± 1.868 | NA ± NA |
| CCN family member 2 (P29279) | 1.245 ± 1.585 | 1.258 ± 1.360 | NA ± NA |
| Urokinase plasminogen activator surface receptor (Q03405) | 1.744 ± 1.699 | 1.725 ± 1.398 | NA ± NA |
| C-C motif chemokine 14 (Q16627) | 3.013 ± 1.667 | 3.056 ± 1.426 | NA ± NA |
| C-C motif chemokine 16 (O15467) | 1.625 ± 1.776 | 1.633 ± 1.637 | NA ± NA |
| Collagen alpha-1(I) chain (P02452) | 0.646 ± 1.675 | 0.693 ± 1.497 | NA ± NA |
| Decorin (P07585) | 1.523 ± 1.233 | 1.526 ± 1.233 | NA ± NA |
| C-C motif chemokine 2 (P13500) | 3.065 ± 1.285 | 3.209 ± 1.367 | NA ± NA |
| Matrix metalloproteinase-9 (P14780) | 1.329 ± 2.202 | 1.176 ± 1.985 | NA ± NA |
| E-selectin (P16581) | 1.235 ± 1.828 | 1.200 ± 1.577 | NA ± NA |
| Thrombospondin-2 (P35442) | 1.421 ± 1.655 | 1.452 ± 1.649 | NA ± NA |
| Retinoic acid receptor responder protein 2 (Q99969) | 2.201 ± 1.580 | 2.252 ± 1.418 | NA ± NA |
| C-X-C motif chemokine 16 (Q9H2A7) | 1.341 ± 1.586 | 1.353 ± 1.338 | NA ± NA |
| Dickkopf-related protein 3 (Q9UBP4) | 1.827 ± 1.541 | 1.925 ± 1.460 | NA ± NA |
Showing the first 100 of 115 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Aug 2021 to primary completion in Dec 2021, 4 months.
Results were first posted in Mar 2023, 1 year 3 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 4 months is below that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
Renal Insufficiency, Chronic →